Skip to content

Alkermes ALKS Investments

Investments at other companies

AbbVie logo
AbbVieABBV
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
TG Therapeutics logo
TG TherapeuticsTGTX

Segments

By geography

See full
IE$48.52M
US$24.63M

Other financials

Income statement

See full
Revenue$392.9M+28.2%
Gross profit$331.3M+28.8%
Operating income-$48.3M-450%
Net income-$66.5M-396%
EPS (diluted)-$0.40-408%

Balance sheet

See full
Cash & equivalents$351.6M-12.1%
Total debt$1.6B+2,034%
Total equity$1.8B+15.9%
Total assets$4.3B+105%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$4.1M-59.5%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$7.5B+9.7%
Enterprise value$8.73B+41.2%
P/E49.1×+29.7×
P/S4.8×+0.3×

Profitability

See full
Gross margin86.6%+2.2pp
Operating margin12.3%-13.6pp
Net margin9.8%-13.5pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity9.4%-16.1pp
Debt / equity0.9×+0.9×
Current ratio2.3×-1.1×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:LongTermInvestments.

The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alkermes's investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alkermes's investments?
Alkermes (ALKS) reported investments of $26.36M in Q1 2026.
How has Alkermes's investments changed year-over-year?
Alkermes's investments decreased by 18.1% year-over-year, from $32.19M to $26.36M.
What is the long-term trend for Alkermes's investments?
Over 5 years (2020 to 2025), Alkermes's investments has grown at a -64.2% compound annual growth rate (CAGR), from $24.78M to $145K.